SCHEMBL1825487

SCHEMBL1825487

CCOC(=O)CC(c1cccc(OS(=O)(=O)c2ccc(C)cc2)c1)C(N)C(=O)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
P2RX7 Q99572 9/20 0.41
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
G6PD P11413 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
F10 P00742 1/20 0.38
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
MEN1 O00255 1/20 0.36
SLC15A1 P46059 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827318 0.96 LMNA (0.45) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1824782 0.95 SMN1; SMN2 (0.41) LMNAP2RX7KMT2ASMN1; SMN2GAA
SCHEMBL1828158 0.93 LMNA (0.41) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1823394 0.91 LMNA (0.40) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1823734 0.91 P2RX7 (0.45) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1828893 0.90 P2RX7 (0.47) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL1824503 0.90 SMN1; SMN2 (0.44) LMNAKMT2ASMN1; SMN2SLC15A1
SCHEMBL1826786 0.89 P2RX7 (0.45) LMNAP2RX7KMT2ASMN1; SMN2MAPT
SCHEMBL3578426 0.88 KMT2A (0.43) KMT2ASMN1; SMN2F10SLC15A1
SCHEMBL1825023 0.87 P2RX7 (0.40) LMNAP2RX7KMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 LMNA 1802/4885P2RX7 3606/4885KMT2A 1068/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 LMNA 1130/4885P2RX7 2747/4885KMT2A 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.